Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
400 participants
INTERVENTIONAL
2017-06-01
2021-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Due to biologic medication's efficacy and safety profiles, they have revolutionized dermatology and the general medical field. However, patients may be apprehensive about choosing a biologic medication for a variety of reasons. These include hearing negative information about the drug from friends or family, being nervous about injection, or seeing the drug or its side effects negatively portrayed in the media. Many patients are not aware that clinical trial evidence for biologics exist, and instead may rely on anecdotal evidence in choosing to take these medications.
Because fear of the drug is inherently subjective, it can be modified with appropriate reassurance and presentation of evidence. Physicians must be able to ascertain from where the fear originates and how it can be countered. By understanding what kind of information will allow patients to be confident in their decision to take a biologic, dermatologists can improve outcomes and initiate use of this drug. Furthermore, reducing fear of side effects or adverse events may improve adherence to treatment and may improve treatment outcomes. The investigators propose this study with the goal of learning whether patients are more confident in the potential success of biologic medications in treating their psoriasis after being presented with clinical trial evidence, anecdotal evidence, or both.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis
NCT03465696
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
NCT01971346
Biologics Anchoring Study
NCT03026153
Understanding Participation Habits Among Plaque Psoriasis Patients
NCT06338358
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
NCT07129382
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anecdotal Evidence
Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
Anecdotal Evidence
Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
Research Study Evidence
Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
Research Study Evidence
Communicate basic information on the therapeutic effect of a drug using only research study evidence.
Anecdotal + Research Study Evidence
Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
Anecdotal + Research Study Evidence
Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
No Evidence
Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.
No Evidence
Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anecdotal Evidence
Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
Research Study Evidence
Communicate basic information on the therapeutic effect of a drug using only research study evidence.
Anecdotal + Research Study Evidence
Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
No Evidence
Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-80
Exclusion Criteria
* Currently or previously managed with a biologic medication
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wake Forest University Health Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steve R Feldman, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00043948
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.